MAPT and supranuclear palsy, progressive, 1: PET studies with[18F-]PI6240, [18F-]MK6240,and [18F-]PM-PBB3 have been reported in the literaturefor the AD, PSP, and CBD patients.17,19−22,39,41 These studies clearly demonstrate that MK6240 shows no significantbinding in PSP and CBD patients and therefore can discriminate ADfrom other tauopathies by its selective binding in the brain of ADpatients.17 This observation is in agreementwith the in vitro binding studies discussed aboveand is also the reason why in the present study MK6240 was not selectedfor the metadynamics simulations for CBD tau.